Smith Karen L. has filed 16 insider transactions across 4 companies since June 2024.
Most recent transaction: a grant/award of 75000 shares of Skye Bioscience, Inc. ($SKYE) on March 31, 2026.
Activity breakdown: 0 open-market purchases and 1 sale.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | Skye Bioscience, Inc. | $SKYE | Smith Karen L. | Director | A | Stock Option (Right to Buy) | 75000 | $0.00 | 75,000.0000 | 39,665,927 | 9999.99% | 0.19% |
| Feb. 6, 2026 | Skye Bioscience, Inc. | $SKYE | Smith Karen L. | Director | A | Stock Option (Right to Buy) | 35000 | $0.00 | 35,000.0000 | 39,665,927 | 9999.99% | 0.09% |
| June 12, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Smith Karen L. | Not found | A | Stock Option (Right to Buy) | 50000 | $0.00 | 50,000.0000 | 224,710,019 | 9999.99% | 0.02% |
| June 12, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Smith Karen L. | Not found | A | Common Stock | 25000 | $0.00 | 102,100.0000 | 224,710,019 | 32.43% | 0.01% |
| June 12, 2025 | Context Therapeutics Inc. | $CNTX | Smith Karen L. | Director | A | Stock Option (right to buy) | 123500 | $0.00 | 123,500.0000 | 58,416,141 | 9999.99% | 0.21% |
| Feb. 24, 2025 | Skye Bioscience, Inc. | $SKYE | Smith Karen L. | Director | A | Stock Option (Right to Buy) | 35000 | $0.00 | 35,000.0000 | 36,486,519 | 9999.99% | 0.10% |
| Nov. 21, 2024 | Aurinia Pharmaceuticals Inc. | $AUPH | Smith Karen L. | Director | A | Common Shares | 12135 | $0.00 | 24,807.0000 | 145,651,000 | 95.76% | 0.01% |
| Nov. 21, 2024 | Aurinia Pharmaceuticals Inc. | $AUPH | Smith Karen L. | Director | A | Director Stock Option (right to buy) | 18641 | $0.00 | 18,641.0000 | 145,651,000 | 9999.99% | 0.01% |
| Nov. 8, 2024 | Aurinia Pharmaceuticals Inc. | $AUPH | Smith Karen L. | Director | M | Common Stock | 17913 | $0.00 | 17,913.0000 | 145,651,000 | 9999.99% | 0.01% |
| Nov. 11, 2024 | Aurinia Pharmaceuticals Inc. | $AUPH | Smith Karen L. | Director | S | Common Stock | 5241 | $8.43 | 12,672.0000 | 145,651,000 | 29.26% | 0.00% |
| Nov. 8, 2024 | Aurinia Pharmaceuticals Inc. | $AUPH | Smith Karen L. | Director | M | Restricted Stock Units | 17913 | $0.00 | 0.0000 | 145,651,000 | 100.00% | 0.01% |
| Oct. 28, 2024 | Skye Bioscience, Inc. | $SKYE | Smith Karen L. | Director | A | Stock Option (Right to Buy) | 70000 | $0.00 | 70,000.0000 | 38,819,387 | 9999.99% | 0.18% |
| Sept. 4, 2024 | Context Therapeutics Inc. | $CNTX | Smith Karen L. | Director | A | Stock Option (right to buy) | 19315 | $0.00 | 19,315.0000 | 15,966,053 | 9999.99% | 0.12% |
| July 2, 2024 | Skye Bioscience, Inc. | $SKYE | Smith Karen L. | Director | A | Director Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 7,006,038 | 9999.99% | 0.57% |
| June 4, 2024 | SANGAMO THERAPEUTICS, INC | $SGMO | Smith Karen L. | Not found | A | Stock Option (Right to Buy) | 50000 | $0.00 | 50,000.0000 | 0 | 9999.99% | 0.00% |
| June 4, 2024 | SANGAMO THERAPEUTICS, INC | $SGMO | Smith Karen L. | Not found | A | Common Stock | 25000 | $0.00 | 77,100.0000 | 0 | 47.98% | 0.00% |